Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
HOME > August 29, 2024
Daily News
August 29, 2024
- MHLW Requests Funds for Adding PMDA Reviewers, Subsidizing Advisory Fees in FY2025
August 29, 2024
- MHLW to Seek Nearly 800 Million Yen to Boost New Modalities: FY2025 Budget Request
August 29, 2024
- Personal Info of Over 700,000 People Potentially Leaked: Sanofi Japan
August 29, 2024
- MHLW’s Tax Reform Request Not Yet Clear, HSC Debate Might Be a Cue
August 29, 2024
- LDP Health Division OKs MHLW’s FY2025 Budget Request
August 29, 2024
- Sawai Nabs Distribution Rights to CureApp’s Alcoholism Therapy App
August 29, 2024
- Chugai to Divest Oxarol Injection to LTL in Japan
August 29, 2024
- Padcev-Keytruda Approved in Europe for 1st Line Bladder Cancer
August 29, 2024
- Takeda Rolls Out CMV Drug Livtencity in Japan
August 29, 2024
- NCGM President to Take Helm of Japan CDC after April Merger
August 29, 2024
- Trintellix, Vtama Get 2-Year Extension of Re-Examination Period
August 29, 2024
- Japan Doles Out Orphan Tags for 10 APIs, Pulls Status for Biogen’s MS Drug
August 29, 2024
- Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…